| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/13/2002 | CN1340043A Phenylalaninol derivatives |
| 03/13/2002 | CN1339963A Spontaneously dispersible N-benzoyl staurosporine compositions |
| 03/13/2002 | CN1339955A Gels formed by the interaction of poly(aldehyde) with various sabstances |
| 03/13/2002 | CN1339436A Method for preparing xitaipulan |
| 03/13/2002 | CN1339435A Method for preparing xitaipulan |
| 03/13/2002 | CN1339316A Medicine for curing child brain paralysis |
| 03/13/2002 | CN1080718C Vitamin D amine and amine derivatives |
| 03/13/2002 | CN1080562C Use of prostance derivatives and the combination with antibiotics in the treatment of bacterial infections |
| 03/13/2002 | CN1080560C Oral medicinal liquor for abstaining from taking drug and production technology thereof |
| 03/12/2002 | US6355809 Method for preparing (2s)-1-(2r3s)-5-chloro-3-(2-chlorophenyl) -1-(3,4-dimethoxy benzene-sulphonyl) 3-hydroxy-2,3-dihydro-1h-indole-2-carbonyl pyrrolidine-2-carboxamide |
| 03/12/2002 | US6355805 β3-adrenergic receptor agonists |
| 03/12/2002 | US6355798 Ligands for gamma-aminobutyric acid receptors; anticonvulsants, anxiolytic agents |
| 03/12/2002 | US6355690 Remedy for CAG repeat expansion diseases |
| 03/12/2002 | US6355689 Antiinflammatory agents |
| 03/12/2002 | US6355680 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 03/12/2002 | US6355670 Skin disorders |
| 03/12/2002 | US6355668 Bicycloloactam compounds, use thereof and intermediates for preparing thereof |
| 03/12/2002 | US6355666 Protected forms of pharmacologically active agents and uses therefor |
| 03/12/2002 | US6355662 Peptide and nonpeptides autoimmune diseases, antiinflammatory agents |
| 03/12/2002 | US6355655 Treating a cognitive disorder, a neuro-degenerative disorder; age-related dementia; age-induced memory impairment; a movement disorder, attention deficit disorder; attention deficit hyperactivity disorder; psychosis; cognitive deficits |
| 03/12/2002 | US6355653 Amino-triazolopyridine derivatives |
| 03/12/2002 | US6355651 Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
| 03/12/2002 | US6355650 Leukocyte antiadhesion agents |
| 03/12/2002 | US6355647 3-substituted 3,4,5,7-tetrahedropyrrolo[3′,4′:4,5]thieno-[2,3-d]pyrimidine derivatives, their preparation and use |
| 03/12/2002 | US6355642 Tetrahydrobenzindole compounds |
| 03/12/2002 | US6355640 Pyrazolopyridine adenosine antagonists |
| 03/12/2002 | US6355638 Pyrazolo[1,5-d][1,2,4] triazines for enhancing cognition |
| 03/12/2002 | US6355618 Enzyme inhibitors |
| 03/12/2002 | US6355617 Peptide derivatives |
| 03/12/2002 | US6355613 Cyclized oligopeptides with bridging groups of amide, thioether, thioester or disulfide |
| 03/12/2002 | US6355612 Protein material for slow digestion and its use |
| 03/12/2002 | US6355265 Over-coated chewing gum formulations |
| 03/12/2002 | US6355258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form |
| 03/12/2002 | CA2137889C Eburnan analogs; process for preparing the same and pharmaceutical compositions containing them |
| 03/12/2002 | CA2064077C T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| 03/12/2002 | CA2060393C Carbamic acid derivatives and method for preparing the same |
| 03/12/2002 | CA2055947C Condensed heterocyclic compounds, their production and use |
| 03/07/2002 | WO2002019213A2 Method for treatment of migraine using pde5 inhibitors |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018593A2 Modulation of fas and fasl expression |
| 03/07/2002 | WO2002018585A2 Packaging of positive-strand rna virus replicon particles |
| 03/07/2002 | WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018575A2 Genes expressed in the cell cycle |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018548A2 Tyrosine hydroxylase 5' control elements and uses thereof |
| 03/07/2002 | WO2002018540A2 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018434A2 Proteins related to schizophrenia and uses thereof |
| 03/07/2002 | WO2002018401A2 Novel synthetic gangliosides |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018390A1 Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
| 03/07/2002 | WO2002018387A1 2,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonvulsive action and methods for producing the same |
| 03/07/2002 | WO2002018386A1 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
| 03/07/2002 | WO2002018385A1 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES |
| 03/07/2002 | WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 03/07/2002 | WO2002018381A1 6,7-dihydro-pyrrolo[3,4-b]pyridin-5-ones with an anticonvulsive action and methods for producing the same |
| 03/07/2002 | WO2002018380A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | WO2002018379A2 7-oxo pyridopyrimidines |
| 03/07/2002 | WO2002018367A1 Tetrahydrobenzindole derivatives capable of binding to 5-ht7 receptor and metabolically stable |
| 03/07/2002 | WO2002018358A1 N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide |
| 03/07/2002 | WO2002018350A1 Grk inhibitor |
| 03/07/2002 | WO2002018348A2 Quinazoline derivatives as alpha-1 adrenergic antagonists |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | WO2002018338A1 Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |
| 03/07/2002 | WO2002018334A2 Sodium channel modulators |
| 03/07/2002 | WO2002018333A1 Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors |
| 03/07/2002 | WO2002018330A1 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| 03/07/2002 | WO2002017971A1 Slow release pharmaceutical preparation and method of administering same |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017954A1 Antiparkinsonism drugs |
| 03/07/2002 | WO2002017953A2 Thrombomodulin analogs for use in recovery of signal cord injury |
| 03/07/2002 | WO2002017951A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | WO2002017944A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | WO2002017943A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | WO2002017942A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | WO2002017941A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | WO2002017940A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | WO2002017930A2 Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017921A2 Paroxetine compositions and processes for making the same |
| 03/07/2002 | WO2002017920A2 Use of methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017919A2 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017896A2 Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
| 03/07/2002 | WO2002017895A2 Use of an aldosterone receptor antagonist to improve cognitive function |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | WO2002017889A1 Transdermal therapeutic system for releasing venlafaxine |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001093802A3 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001089474A3 O/w emulsion |
| 03/07/2002 | WO2001078757A3 Reversible immortalization |
| 03/07/2002 | WO2001078649A3 Pharmaceutical curative compound |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001068112A3 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |